文献速递肝病消化道肿瘤与早癌

β-catenin突变肝细胞癌中谷氨酰胺合成酶缺失通过巨噬细胞代谢重编程促进肿瘤负荷

Glutamine synthetase loss in β-catenin-mutant hepatocellular carcinoma promotes tumor burden through macrophage metabolic reprogramming.
PubMed 文献 · Hepatology · 2025-10-23

研究探讨β-catenin突变肝细胞癌中谷氨酰胺合成酶(GS)缺失的影响。TCGA分析显示CTNNB1突变且Glul低表达的HCC患者生存期差。小鼠模型中肿瘤GS缺失通过上调巨噬细胞Glul导致代谢适应、mTOR激活和免疫抑制,巨噬细胞清除或条件性敲除Glul可减少肿瘤负荷并改善生存。

要点

  • CTNNB1突变HCC中GS低表达与患者生存期差相关
  • 肿瘤GS缺失迫使巨噬细胞上调Glul,改变其代谢和免疫功能
  • 靶向巨噬细胞Glul或清除巨噬细胞可减轻肿瘤负荷

核心结论

  • β-catenin突变HCC对肿瘤细胞GS有独特代谢依赖,GS缺失后该依赖转移至巨噬细胞,改变巨噬细胞代谢和功能,导致免疫监视受损和肿瘤负荷增加。

研究设计与样本

  • 研究评估TCGA中CTNNB1突变HCC伴差异Glul表达对生存的影响,并在小鼠HCC模型中条件性敲除肝细胞和/或巨噬细胞的Glul,同时使用氯膦酸盐清除巨噬细胞。
  • 肿瘤通过组织学和单细胞空间转录组学进行表征。

主要发现

  • CTNNB1突变且Glul低表达的HCC患者生存期差。
  • β-catenin突变HCC缺乏GS时,谷氨酸/谷氨酰胺可用性改变迫使代谢适应,上调巨噬细胞Glul,允许mTOR激活并对mTOR抑制剂敏感,但使巨噬细胞功能从免疫监视转向免疫抑制。
  • 肿瘤Glul缺失不影响β-catenin依赖的肿瘤分区和对β-catenin抑制的反应性。
  • 在GS缺陷的β-catenin突变HCC中,氯膦酸盐清除巨噬细胞或条件性敲除巨噬细胞Glul可减少肿瘤负荷并改善生存。

临床怎么用

  • 对于CTNNB1突变且GS低表达的HCC患者,靶向巨噬细胞Glul或清除巨噬细胞可能减少肿瘤负荷并改善生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Activating β-catenin gene ( CTNNB1 ) mutations are seen in 30% of all hepatocellular cancer (HCC). These tumors are a molecularly distinct subclass characterized in the majority of cases by the presence of tumor-wide glutamine synthetase (GS), increased glutamine, mTOR activation, and susceptibility to mTOR inhibitors. Here, we investigate the impact of GS loss from β-catenin-mutated HCCs. APPROACH: TCGA was assessed for CTNNB1 -mutated HCCs with differential Glul (encoding GS) expression for survival. Glul was conditionally deleted from hepatocytes and/or macrophages in HCCs co-expressing mutant- CTNNB1 (T41A) and mutant Nrf2 in mice. Macrophage depletion was also performed by Clodranate treatment. Tumors were characterized by histology and single-cell spatial transcriptomics. RESULTS: CTNNB1 -mutated HCC patients with low Glul showed poor survival. β-Catenin-mutated HCCs lacking GS exhibited aggressive disease due to altered glutamate/glutamine availability, forcing metabolic adaptation through upregulation of macrophage Glul , permitting mTOR activation and susceptibility to mTOR inhibitors, but switching macrophage function from immunosurveillance to immunosuppression. Glul loss from tumors did not interfere with β-catenin-dependent tumor zonation and responsiveness to β-catenin inhibition. Depleting macrophages using clodronate or conditionally deleting Glul from macrophages in GS-deficient, β-catenin-mutant HCCs decreased tumor burden and improved survival. CONCLUSIONS: We demonstrate the unique metabolic dependency of β-catenin-mutated HCCs on GS in tumor cells, which is diverted to macrophages upon GS elimination in tumor cells. This adaptation alters macrophage metabolism and function, leading to compromised immunosurveillance and greater tumor burden. Our study reveals a metabolic dynamic between HCC cells and macrophages with an impact on tumor biology.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Delgado ER, Patel P, Tao J, et al. Glutamine synthetase loss in β-catenin-mutant hepatocellular carcinoma promotes tumor burden through macrophage metabolic reprogramming. Hepatology. 2025. PMID: 41129335. doi:10.1097/HEP.0000000000001591

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。